US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.38

-0.0200-1.43%

Post-market: 1.410.0282+2.04%16:19 EDT

Volume:176.21K

Turnover:246.65K

Market Cap:195.14M

PE:6.44

High:1.44

Open:1.42

Low:1.36

Close:1.40

52wk High:27.36

52wk Low:1.27

Shares:141.41M

Float Shares:41.01M

Volume Ratio:0.46

T/O Rate:0.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

EPS(LYR):-5.8037

ROE:-871.42%

ROA:-49.99%

PB:-10.06

PE(LYR):-0.24

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/VRXA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.38,"timestamp":1788379200000,"preClose":1.4,"halted":0,"volume":176209,"hourTrading":{"tag":"盘后","latestPrice":1.4082,"preClose":1.38,"latestTime":"16:19 EDT","volume":1670,"amount":2350.1201920000003,"timestamp":1788380361884,"change":0.0282,"changeRate":0.020435,"amplitude":0.020435},"delay":0,"changeRate":-0.0142857142857143,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"Post-Mkt","change":-0.02,"latestTime":"09-02 17:09:06 EDT","open":1.42,"high":1.435,"low":1.36,"amount":246646,"amplitude":0.053571,"askPrice":1.52,"askSize":9044,"bidPrice":1.36,"bidSize":250,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.4,"preHourTrading":{"tag":"盘前","latestPrice":1.414,"preClose":1.4,"latestTime":"08:13 EDT","volume":4223,"amount":6365.2544198,"timestamp":1788351217777,"change":0.014,"changeRate":0.01,"amplitude":0.121429},"postHourTrading":{"tag":"盘后","latestPrice":1.4082,"preClose":1.38,"latestTime":"16:19 EDT","volume":1670,"amount":2350.1201920000003,"timestamp":1788380361884,"change":0.0282,"changeRate":0.020435,"amplitude":0.020435},"volumeRatio":0.459244},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":0.459244,"shares":141407813,"dividePrice":0,"high":1.435,"amplitude":0.053571,"preClose":1.4,"low":1.36,"week52Low":1.27,"pbRate":"-10.06","psRate":"6771.69","week52High":27.36,"institutionHeld":0,"latestPrice":1.38,"committee":-0.946202,"eps":0.2142,"divideRate":0,"volume":176209,"delay":0,"ttmEps":0.2142,"open":1.42,"prevYearClose":18.65,"prevWeekClose":1.35,"prevMonthClose":1.35,"prevQuarterClose":1.88,"fiveDayClose":1.64,"twentyDayClose":1.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-09-01","current":6.442577,"percent":0.875,"low":-1.401348,"twenty":-1.340461,"median":-1.249249,"eighty":-0.788262,"high":-0.413162,"avg":-1.073718,"sd":0.366604,"marketCap":34043375},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-01","current":-0.414674,"twenty":-1.340461,"median":-1.249249,"eighty":-0.788262,"marketCap":34043375}],"updateTime":1788383346341},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664888755","title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888755","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888755?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207055,"startTime":"0","endTime":"0","summary":"Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650Veraxa Biotech CEO, director Christoph Rudiger Antz reported a purchase of 5,000 ordinary shares.The shares were bought at ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5ghMkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530737","title":"VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:00","pubTimestamp":1787670008,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 25th, 2026, FinanceWire Following completion of the initial phase of its collaboration with OmniAb, VERAXA wil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQY","ONEQ","XBI","IYW","JEPQ","QYLG","BK4588","QLD","QQQA","QQQJ","BK4585","QDTE","NQmain","PSQ","QID",".IXIC","QQQY","TECS","TQQQ","NVIW.SI","MNQmain","QQQE","BK4139","QQQM","BK4581","QQQ","GPIQ","VRXA","SQQQ","FTEC","NDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662083312","title":"VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision","url":"https://stock-news.laohu8.com/highlight/detail?id=2662083312","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662083312?lang=en_us&edition=fundamental","pubTime":"2026-08-25 01:00","pubTimestamp":1787590833,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 24th, 2026, FinanceWire VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer ce...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONEQ","QQQA","QQQE","TQQQ","MNQmain","TECS","BK4588","TQQY","BK4585","VRXA",".IXIC","JEPQ","QQQM","NQmain","BK4581","GPIQ","IYW","QYLG","QID","QQQ","SQQQ","QQQY","QDTE","BK4139","PSQ","NDX","FTEC","NVIW.SI","QQQJ","QLD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661427591","title":"Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2661427591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661427591?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:41","pubTimestamp":1787571679,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L08R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VRXA\",params:#limit:6,delay:false,,,undefined,":[]}}